{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:07:55Z","timestamp":1772107675934,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012 to 2015. Propensity score (PS)-weighted Cox proportional hazards model was used to estimate hazard ratios (HRs) for CKD progression and improvement. A separate analysis was conducted to assess the HR for CKD progression and CKD recovery among those with worsening CKD.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of CKD progression among allopurinol, febuxostat and uricosuric agent users were 1.98, 1.88 and 1.64 per 1000 person-days. Compared with allopurinol users, the PS-weighted HR (95% confidence intervals [CIs]) was 1.77 (0.85\u20131.76) for febuxostat users and 1.37 (0.71\u20131.37) for uricosuric agent users for CKD progression and 1.43 (1.26\u20131.62) for febuxostat users and 1.00 (0.88\u20131.14) for uricosuric agent users for CKD improvement. Compared to allopurinol users, the HRs for CKD progression were 1.14 (0.80\u20131.66) for febuxostat users and 0.92 (0.67\u20131.31) for uricosuric agent users. Among 741 patients who had CKD progression, the incidence of CKD recovery was 1.33, 6.21 and 3.53 per 1000 person-days for allopurinol, febuxostat and uricosuric agent users. The HRs (95% CIs) for recovery in febuxostat and uricosuric agent users were 2.17 (1.40\u20133.47) and 1.80 (1.20\u20132.83) compared to allopurinol users.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CKD progression and recovery are common in gout patients using ULDs. Febuxostat and benzbromarone were associated with a similar risk of CKD progression with allopurinol, which has a poorer recovery compared with other ULDs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-019-1993-9","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T13:04:57Z","timestamp":1568811897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Ting-Ting","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang-Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-5730","authenticated-orcid":false,"given":"Chang-Fu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shue-Fen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Jiun","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ching","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yi","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao-Ho","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-Chin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"11","key":"1993_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1993_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"CF Kuo","year":"2016","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1993_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101\u20136.","journal-title":"Hypertension."},{"issue":"4","key":"1993_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0022-5347(17)54561-9","volume":"126","author":"TF Yu","year":"1981","unstructured":"Yu TF. Urolithiasis in hyperuricemia and gout. J Urol. 1981;126(4):424\u201330.","journal-title":"J Urol"},{"key":"1993_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/art.1780050406","volume":"5","author":"GR Thompson","year":"1962","unstructured":"Thompson GR, Duff IF, Robinson WD, Mikkelsen WM, Galindez H. Long term uricosuric therapy in gout. Arthritis Rheum. 1962;5:384\u201396.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1993_CR6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1993_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/DTI.S16524","volume":"8","author":"T Akimoto","year":"2014","unstructured":"Akimoto T, Morishita Y, Ito C, Iimura O, Tsunematsu S, Watanabe Y, et al. Febuxostat for hyperuricemia in patients with advanced chronic kidney disease. Drug Target Insights. 2014;8:39\u201343.","journal-title":"Drug Target Insights"},{"issue":"1","key":"1993_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7\u201313.","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"1993_CR9","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68(8):2035\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1993_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/15257770.2011.622732","volume":"30","author":"S Fujimori","year":"2011","unstructured":"Fujimori S, Ooyama K, Ooyama H, Moromizato H. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1035\u20138.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"3","key":"1993_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895\u2013900.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1993_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1993_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1993_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"1993_CR15","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388\u2013414.","journal-title":"Stat Med"},{"issue":"6","key":"1993_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601\u20139.","journal-title":"Circulation."},{"issue":"3\u20134","key":"1993_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10742-016-0168-2","volume":"17","author":"L Parast","year":"2017","unstructured":"Parast L, McCaffrey DF, Burgette LF, de la Guardia FH, Golinelli D, Miles JNV, et al. Optimizing variance-bias trade-off in the TWANG package for estimation of propensity scores. Health Serv Outcome Res Methodol. 2017;17(3\u20134):175\u201397.","journal-title":"Health Serv Outcome Res Methodol"},{"issue":"6","key":"1993_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-93-6-817","volume":"93","author":"FH Messerli","year":"1980","unstructured":"Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93(6):817\u201321.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1993_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239\u201347.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1993_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/ndt\/gfm790","volume":"23","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant. 2008;23(4):1265\u201373.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1993_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1993_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/03009742.2010.507218","volume":"40","author":"CF Kuo","year":"2011","unstructured":"Kuo CF, Luo SF, See LC, Ko YS, Chen YM, Hwang JS, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol. 2011;40(2):116\u201321.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"1993_CR23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","volume":"178","author":"AB Vargas-Santos","year":"2018","unstructured":"Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med. 2018;178(11):1526\u201333.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1993_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1993_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","volume":"65","author":"M Goicoechea","year":"2015","unstructured":"Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65(4):543\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1993_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23876\/j.krcp.2017.36.3.274","volume":"36","author":"S Kim","year":"2017","unstructured":"Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, et al. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: a systematic review and meta-analysis. Kidney Res Clin Pract. 2017 Sep;36(3):274\u201381.","journal-title":"Kidney Res Clin Pract"},{"key":"1993_CR27","unstructured":"Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018;33(9):1620\u201327."},{"issue":"11","key":"1993_CR28","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1993_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/pds.4729","volume":"28","author":"JG Connolly","year":"2019","unstructured":"Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019;28(5):665\u201370.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"1993_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2008.10.005","volume":"62","author":"CL Tsai","year":"2009","unstructured":"Tsai CL, Camargo CA Jr. Methodological considerations, such as directed acyclic graphs, for studying \u201cacute on chronic\u201d disease epidemiology: chronic obstructive pulmonary disease example. J Clin Epidemiol. 2009;62(9):982\u201390.","journal-title":"J Clin Epidemiol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1993-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:37:36Z","timestamp":1600299456000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1993-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the Chang Gung Memorial Hospital (approval number: 201700870B0). The patient consent was exempted for the total animosity of all research data in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}